A B s T R A C T A niewN, proce(dure for the radlioitimutinoassay of i-triiodothyronine ( T:) inl h1uIm1ain plasima is (lescribed in whiclh the iodothivronine.s are separatedl frollm the pl)asma proteins before incubation with a specific anitiserumii to Ta. The antibody bound and free T. are separated with dextran-coated charcoal. In this system, the mean recovery of T added to l)lasma was 97.9% aand botlh in vitro conversion of L-thyroxine (T4) to T:. and crossreaction between T. and the anti-T3 antibody were undetectable (less thani 0.1% ). The assay procedure allowed the measuremiienit of T:, in up to 0.5 ml of plasma resulting in iml)roved assay sensitivity (6 ng/100 ml).
INTRODUCTION
During the last four years considerable attention has beeni paid to the developmienit of mletlhods for measurement of Dr. Oppenheimiier is a Career Scienitist of the Health Re- search Council of the City of New York .
Received for-publicatilon 2? June 1972 (111(1 in rev'ise(d fJr 15 August 1972. the l)lasma conicenitrationi of 3,5,3'-triiodo-L-thyronine T.,).' The interest of miiany ilnvestigators lhas beeni stimuilated by tlhree factors: (a) the wvell-knowvn greater biological activity of T3 compared with L-thvroxine (T4) (1) ; (b) the demonistration by Braverman, lIgbar. andl Sterling (2) that T4 is converted to T3 in vivo; and (c). the recent capability to miieasure To turinover rates in manl (3) .2 These data suggest that the miajor portion of thyroid mletabolic activity may be due to T. rather than T4. The possibility that T4 has no intrinsic biological activity but serves as a prohormone for T3 has been suggestedl (4) (5) (6) (7) . Several methods for the determination of T3 have beeni reported which involve extraction of the iodothyronines from the serunm followed by chromatographic separatioln of To from T4 and measurement of T3 by displacement analysis (8, 9) . These procedures are technically difficult and lhave resulted in overestimation of serum T3 (dile to conversion of T4 to To in vitro or from incomplete separation of T4 fr.om T3 before T3 measurement (10, 11) .
More r&cently, the production of specific antibodies to T: has been achieved (12) (13) (14) (15) , and several reports describing the determination of T. by radioimmunoassay of unextracted plasma have appeared (12, 13, (15) (16) (17) (18) (19) . The current report describes a new procedure for the radioinmnmunoassay of T. which allows measurement of T3 in large serum v-olumes (up to 0.5 nil). The sensitivity of the assay is thereby improved enabling an accurate as-'Abbre,viationis iised in this paper: BSA, bovine serum albumin; RIA, radioimmunoassay; T3, triiodo-L-thyronine; T,. L-tlhyroxinie; B-T:, antibody bound Ts; F-T3, antibody free T,.
2 Surks, M. I., A. R. Schadlow, and J. H. . Determinationi of iodothyroninie absorption and conversion of L-thyroxinie (T4) to L-triiodothyronine (T3) using turnover rate technli(qtues. Suibmitted for puiblication in J. (C1il1. Ilt'z''.s '. sessment of the T3 concentration in hypothyroidism. The concentration of Ta in euthyroid, hypo-and hyperthyroid subjects as well as in hypothyroid patients under treatment with different thyroid hormone preparations will be presented.
M ETHODS
The concentration of T3 in serum or plasma was determined by radioimmunoassay after separation of the hormone from the plasma proteins on small Sephadex columns (20) . The barrels of disposable 3.0 ml syringes (Becton-Dickinson & Co., Rutherford, N. J.) with small glass-wool plugs were used for columns (I.D. = 7 mm). Columns were packed with 3.0 ml of a well-mixed 10%o suspension of Sephadex, G25 fine (Pharmacia) in 0.1 N NaOH. After packing, they were washed with 2.0 ml 0.1 N NaOH and the bottoms were closed. For the development of standard curves, mixtures of 0.1 ml T3-'5I (75 pg), 0.1 ml gravimetrically prepared standard T3 solutions (50-1000 pg/0.1 ml 0.3%o bovine seruni albumin [BSA] in 0.075 M barbital buffer, pH 8.6), and 0.1 ml 0.1 N NaOH were applied to the columns with Pasteur pipettes. When sera were analyzed, 0.02-0.5 ml human serum was substituted for the T3 standards. All of the Ts-"25I in the system was thus added before fractionation on the Sephadex columns. The test tubes in which the samples were prepared were washed with 0.1 N NaOH and the washes were applied to the columns. The columns were then opened. After the samples had percolated through the Sephadex, the columns were washed twice with 1.5 ml 0.075 M barbital, pH 8.6 (barbital buffer), in order to ensure elution of the plasma proteins and to equilibrate the columns at pH 8.6. Studies with different mixtures of serum or albumin enriched with albumin-"'1I and T3-1"I or T4-125I showed that more than 99%o of the plasma proteins but only 4-8% of the applied iodothyronines were eluted by these procedures. The iodothyronines were then eluted with 0.3% BSA in barbital buffer (BSA buffer). First 0.4 ml BSA was applied anid allowed to drain into the column. Four 0.5 ml portions of BSA buffer were then separately applied and the eluates collected as a single pool (approximately 2.0 ml). After gentle mixing, two 0.9 ml portions of the combined B SA eluate from each column were pipetted into disposable 12 x 77 mm plastic test tubes (Falcon Plastics, Los Angeles, Calif.) The tubes were placed in an ice bath and 0.2 ml of a rabbit anti-T3 antibody solution (see below) was added. The tubes were then mixed (Vortex, Scientific Industries, Inc., Springfield, Mass.) and incubated at 4°C. Trial experiments had shown that equilibration between antibody bound and free Ts occurred withina 16 hr. Therefore, after 18-20 hr incubation, the antibody bound (B-T3) and free Ta (F-T3) were separated by the addition of 1.0 ml of a dextran-coated charcoal suspension at 4°C. The charcoal suspension was prepared by mixing equal volumes of 1% solutions in barbital buffer of activated charcoal (Norit A, Fisher Chemical Co., New York) and dextran, clinical grade, mol wt 70,000-90,000 (Nutritional Biochemicals Corp., Cleveland, Ohio). The charcoal and supernatant were separated by centrifugation 15 min after the charcoal solution was added. The counting rates of both the supernatant containing B-T, and the charcoal (F-Ta)
were measured in a Packard Autogamma Spectrometer, Model 410A. Samples were counted for a sufficient time to limit counting error to 5%.
Antibodies to T3 were raised in six rabbits and eight guinea pigs by injection of T3-BSA conjugates which were prepared by the method of Gharib and Mayberry (13, 15) . The Ts: BSA molar ratios of the different preparations of conjugates which were synthesized varied between 7-10: 1 as determined from the recovery of tracer amounts of T8-'I added before conjugation. a mg of conjugate was homogenized in 0.5 ml complete Freund's adjuvant and injected into each animal every 14 days. Blood was collected by cardiac pulcture 1 wk after the fourth injection. Sera from all rabbits and from four of the eight guinea pigs contained antibodies to T3 which were suitable for the radioimmuno*-assay of T3. A rabbit serum (R4-T3-AB-#3) was selected for these studies and used at a final dilution of 1: 8000 in BSA buffer. The binding properties of R4-T3-AB-#3 and various T3 and T4 analogues were not assessed. However, since no significanit differences in T3 concentration were observed in 25 human sera obtained from hypothyroid, euthyroid, and hyperthyroid subjects between assays performed both with R4-T:,-AB-#3 and with a well-characterized rabbit antiserum to Ti (R9, 10/17/70) (kindly supplied by Dr. Robert E. Mayberry) it is doubtful whether small amounts of T3 or T4 analogues which may circulate in the plasma interfere with our T3 measurements.
Ts labeled with '5I (Triomet-"1, specific activity 70-90 mCi/mg), T4-'"I (Tetramet-'ll, specific activity 70 mCi/ mg), and albumin-"1'I were obtained from Abbott Laboratories, North Chicago, Ill. A single T3-"iI preparation was used for 4-6 wvk without purification sinice paper chromatographic analyses demonstrated that these preparations contained 93-96% Ts and less than 2% iodide-"I even after this interval of time. Since the recovery of T3 from the Sephadex columns was not uniform (65-80%o in the 2.0 ml BSA eluate) it was necessary to determine precisely the specific activity of the added tracer so that appropriate corrections for the mass of T3 in the added T3-`1I could be made. The specific activity of each batch of T8-15I was therefore determined by radioimmunoassay by the method outlined by Berson and Yalow (21) . Mixtures of T3 standards (50-400 pg in 0.1 ml BSA buffer) were added to 0.1 ml T3-'2I (50 pg T3 as estimated from the specific activity of T3-'I furnished by the manufacturer). Some tubes contained 0.2 ml and 0.3 ml of the T:-`I tracer solution without nonradiative T3. T3 antibody was added and the volume of all tubes adjusted to 1.1 ml with BSA buffer. After 18-20 hours incubation, B-Ts and F-T3 were separated as described above. A standard curve was plotted (B/F ratios vs. added nonradiative T3) and the mass of T3 in the T3-1'5I solution was determined from the B/F ratios of the tubes containing two-and threefold volumes of tracer solution.
Calculations. Since the BSA eluate from each column was divided (two 0.9 ml samples), two assay tubes were processed for each Sephadex column. The two B/F ratios for each BSA column eluate were plotted against the total T3 in each assay tube and a standard curve was drawn. York) purified by serial paper chromatography (two cycles) in t-amyl alcohol: 2 N NH4OH: hexane, 5: 6: 1 were added to T3-free serum which was then assayed for T3. T3-free serum was prepared by adding 20 ml of a serum pool from euthyroid subjects enriched with T3-125I (0.1 gCi/ml) to 4 g Dowex 1-X2 anion-exchange resin (BioRad Laboratories, Richmond, Calif.). After mixing for 20 hr at 4°C, the serum was separated from the resin by centrifugationi. Fresh resin was added and the procedure was repeated.
As assessed from the counting rates of T-"25I before and after mixing with resin, more than 99% of the T.. was removed from the serum.
Another approach was to assess the generation of T3-'5I after carrying out the assay procedure in the presence of purified T4-l'I. T4-125I, purified as described above for nonradioactive T4, was added to 2.5 ml BSA buffer. A ml of this solution was processed by the Sephadex column procedure described above for the assay of T3. The 2.0 ml BSA buffer eluate containing the eluted iodothyronines was incubated with T3 antibody for 18 hr at 4°C. After incubation, the iodothyronines were extracted with 95% ethanol (four extractions with 10 ml 95% ethanol). T3-`31I was added to the combined ethanol extracts and the amount of Ts-"5I (relative to T4-'5I) was determined by serial chromatography of the T3 area on paper and thin-layer silica gel sheets to constant isotopic ratio (T3-'5I/T3-1'I) as previously described (4). The T3-'I content of the added T4-"I was simultaneously measured by the same procedures in solutions of 2.0 ml BSA buffer which were incubated under the same conditions but had not been subj ected to Sephadex column fractionation.
T4 cross-reaction. The extent of cross-reaction between T4 and T3-antibody was assessed in three experiments by determining the T3 concentration of pooled serum before and after selective removal of T4. T3-free serum was diluted 1: 20 in barbital buffer and enriched with nonradioactive T4 and T3, as well as T3-'25I and T4-131I. The concentration of T3 was measured in eight samples (0.15 ml) from this 1)ool. Eight additional samples (0.5 ml) were applied to inidividual columns containing Sephadex G-25 M (Pharmacia) equilibrated with barbital buffer, pH 8.6. The columnl size and( amount of Sepliadex were identical to that described above for the T3 assay. At pH 8.6. the plasma proteins bind T4 to a greater (legree than T3. Thus, a greaterfraction of the added T3 than the added T, is retained by the Sephadex. The columns were then washed with 3.0 nil barbital buffer and the retained iodothyronines were elutedt in 2.0 ml BSA buffer. T3 antibody was added to two 0.9 ml portions of the eluate and the Ts concentration determined as described above. The recovery of both T4 and T., was calculated from the counting rates of their respective isotopes.
Clinical sttcdies. Serum T3 and T, concentrations were also measured in tlhree euthyroid subjects at frequent intervals throughout the day and in patients with hypothyroidism receiving hormone replacemenit therapy. The hormone preparations which were administered to these patients were L-T, (Cytomel; Smith, Kline & French Laboratories, Philadelphia, Pa.), L-T4 (Synthyroid, Flint Laboratories, Morton Grove, Ill.), L-T4: L-T3 combination, 4: 1 (Euthyroid, Warner-Chilcott Laboratories, Morris Plains, N. J.), and desiccated thyroid (Armour Pharmaceutical Co., Chicago, Ill.). Serum T3 an(d T4 were measured before and at frequent intervals after the various preparations were ingested. After separation by centrifugation, serum or plasma was stored at -20°C.
RESULTS
Methodologic procedures. The capacity of the Sephadex columns to retain Ts when different amounts of plasma were applied was assessed by addition of mixtures of T3-15I in 0.1 N NaOH and 0.1 to 0.5 ml normal plasma to the columns followed by elution of the plasma proteins with 3.0 barbital buffer. Comparison of the counting rates of the Sephadex to that of the added T3-'"I showed that when 0.1-0.3 ml plasma was applied, 95-98% of the T3 was retained by the Sephadex. When the volume of plasma was increased to 0.4-0.5 ml, 83-. 92% of the added Ts was retained. An average of 80% (range: 70-90%) of the Sephadex-bound Ta was eluted by 2.0 ml 0.3% BSA. Thus, the average recovery of Ts in the 2.0 ml BSA eluate was approximately 70%. Since two 0.9 ml portions of the BSA eluates from each column were assayed, the net recovery of Ts in each assay tube averaged 32% (range: 25-35%). Recovery was equally good when sera containing low endogenous Ta concentrations were processed. Essentially similar recoveries for T4 were observed in experiments in which T4-'I was substituted for Ts-'I. The equal recovery of T3 and T4 by these procedures can be attributed to the essentially complete disruption of iodothyronine binding by the plasma proteins at the high pH of the Sephadex columns. The B/F ratios for paired tubes from the same column eluate differed by less than 5%.
In order to determine whether the Ts-free serum or the Sephadex contained substances which under the conditions of the assay might displace Ts from Ta antibody, 0.1 ml 0.1 N NaOH alone or with 0.3 ml Ta-free serum were applied to separate Sephadex columns followed by 3.0 ml barbital buffer and 2.0 ml BSA buffer. Duplicate 0.9 ml portions from each column BSA eluate were added to tubes containing Ts-'I (50 pg) and Ta-antibody. The B/F ratios in these tubes were identical to those of other tubes which contained fresh BSA buffer, indicating that no interfering substances were present in either the Sephadex or serum. In the same assays, the addition of 10 pg Ts reproducibly decreased the B/F ratio. 1). Since, in three experiments, substitution of BSA buffer for Ta-free serum resulted in standard curves which were indistinguishable from those in which Tafree serum was used, all subsequent curves were set up in BSA buffer. Standard curves developed as described above were also compared with curves derived from incubating comparable mixtures with the exception that fresh BSA was used instead of the column eluates. Although the curves with fresh BSA and BSA from column eluates were generally superimposable, they occasionally diverged in the area of the lowest B/F ratios. Thus, for assay of plasma, standard curves using the Sephadex columns were always employed.
Since the recovery of Ts in the Sephadex column BSA eluates was not significantly reduced when up to 0.5 ml plasma was applied, the assay procedure allowed flexibility in the selection of appropriate volumes of plasma for assay so that the B/F ratio would fall in the most sensitive portion of the standard curve. Fig. 2 shows that the Ts concentrations of different volumes of plasma from representative hypothyroid, euthyroid, and hyperthyroid subjects varied less than 10% from the average of three to five determinations. The constancy of the Ts concentration when different volumes of the same plasma were assayed and the lack of detectable crossreaction with other moieties in plasma indicates that the observed changes in B/F ratio reflect displacement of T8-'I from antibody by endogenous Ts.
In practice, the assay of 0.1 to 0.2 ml plasma from euthyroid subjects, 0.24.4 ml from hypothyroid subjects and 0.02-0.08 ml plasma from hyperthyroid subjects resulted in B/F ratios which fell in the steepest The T3 concentration of the T3-free serum was undetectable to 5 ng/100 ml. T4 was purified by two cycles of paper chromatography in t-amyl alcohol:2N NH40H:hexane, 5:6:1. Nonpurified or purified T4 was added to 0.1 ml T3-free serum. The T3 content of the T3-free serum (0.1 ml) was less than 5 pg. T3/T4 = 100 X moles T3/molesI14. (sample subjected to complete T3 assay procedure).
As little as 0.5% conversion of T4 to T3 in vitro or cross-reaction between T4 and Ta antibody will result in a 30-50% overestimation of the Ta concentration in normal serum. Both of these potential sources of error were therefore carefully examined in the current assay. T4 to T3 conversion was studied by measuring the Ta content of T3-free serumli which had been enriched witlh T4. For three separate lots of T4 the measured T3 was equivalent to 1.05%,, (1range: 0.94-1.12%) of the T, added (Table II) . After chromatographic purificationi of the T4 preparations, thle iriean observed T8 was substantially reduced to 0.36% (range: 0.23-0.45%). Since in pilot studies, the generatioln of 0.2-0.4%; T3 during serial paper chromatographic purification of T4 has repeatedly been observed in this laboratory, it was considered probable that the T3 measured after addition of chromatographically purified T., was a result of residual T8 in the T4 preparations and not to T4 to T3 conversion. Other experiments were therefore designed in which the percentage of T3a 9251was measured after purified T4-_2"j was lprocessed thlrouglh the Sephadex columns and incubated with T: anitibody (Table III) . In two experiments, the percentage of T3-"I (100 X T3-'25I/T4-"I) observed after the Sephadex column procedure and that of the added T4-"I' were indistinguishable within the limits of precision of the chromatographic analyses. Thus, it was concluded that no detectable T4 to T3 conversion (less than 0.1%) occurredl during the assay procedure.
The In two experiments no change in T3 concentration vas observed after repeated freezing and thawing (six times in 24 hr) or after plasma was allowed to stand at room temperature for 24 hr. The Ta concentration was unaltered after storage for at least two months at -20°C. Sensitivity. The lowest Ts concentration detectable depends on the maximum volume of serum which can be introduced into the assay (0.5 ml), the recovery of T8 in the assay tubes and the sensitivity of the standard curve. Since a significant reduction in B/F ratio is regularly observed with the addition of 10 pg Ts, the lowest limit of detection is 10 pg Ta * . recovery (average 33%) = 30 pg. This is equivalent to a concentration of 6 ng/100 ml when a 0.5 ml serum sample is assayed (30 pg . 0.5 X 100).
Precision. The mean coefficient of variation for 8- Clinical studies. The concentration of T3 in the serum or plasma of euthyroid. hypothyroid, and hyperthyroid subjects is shown in Fig. 3 . In euthyroid subjects, the range of T3 concentration was 100-196 ng/ 100 ml. In this group the mean serum T. was 146±24 (SD) ng/100 ml. The mean T: concentration in 29 hypothyroid patients was 44±26 ng/100 ml. None of the values in the hypothyroid group fell within 2 SD of the mean of the euthyroid group. The T. concentration generally correlated with the severity of hypothyroidism. The lowest value, 7 ng/100 ml, was found in a patient in myxedema coma. In other patients with severe hypothyroidism, serum T8 concentration was generally between 10 and 30 ng/100 ml. In tients, mean serunm T3 concentration was 665+±289 ng/ 100 ml. The lowest value in this group, 289 ng/100 ml, occurred in a patient with clinically mild hyperthyroidism due to Graves' disease. No cases of Ta thyrotoxicosis were encountered in a 6 month interval in which 19 consecutive hyperthyroid patients were studied. Plasma T3 and T4 concentrations were measured at frequent intervals during a 24 hr period in three euthyroid subjects. As shown in Fig. 4 , the plasma levels of both hormones were relatively constant throughout the day. The concentration of T4 added to the 1/20 diluted T3-free serum was 8 ug/100 ml. T3 expected was calculated as the product initial T3 concentration and recovery T3-1251 from the Sephadex columns. The calculated cross-reaction was based on the precision of the T3 determinations, recovery of T3-l25I and T4-'3'1, and the extent of change in the T4/T3 ratio. Cross-reaction was calculated by determining if the difference between the T3 expected and the T3 observed could be accounted for by a fraction of the T4 remaining after Sephadex chromatography. T3 concentration is expressed as mean ±SD for eight samples. Serumii 13 aind T4 conceintratioins were also miieasured in hypothyroid patients who were maintained euthyroid ly treatment with different thyroid medications. Sera were obtained at frequent intervals (1-2 hr) after the entire daily dose of medication was ingested. After T3 ingestion, the plasma T3 concentration of four subjects, initially in the normal range, increased to peak values of 450-700 ng/100 ml within 1-2 hr (Fig. 5 ). Thereafter, T3 concentration decreased toward the normal range. 24 hr after ingestion, just before administration of the next daily dose, plasma T3 concentration had returned to the initial euthyroid values. An entirely different pattern of hormone concentrations was observed in four patients who were taking L-thyroxine (Fig. 6 ). Plasma T3 concentration remained essentially unchanged throughout the 24 hr after ingestion of T4. Plasma T.t, however, increased transiently 20-40% in three of four patients studied within the first 5 hr after hormone administration. In the patients treated with T4: T3, 4: 1 mixtures (Fig. 7) or desiccated thyroid (Fig. 8 ) the serum T4 concentration was relatively constant throughout the day. The pattern of T3 concentration was, however, quite variable after ingestion of these medications. After the synthetic T4: T3 mixture plasma T3, initially at or slightly above the upper limit of the normal range, increased transiently to levels which ranged from 320 to 450 ng/100 ml. The increase occurred within the first 1-2 hr in one patient but not until 4-8 hr in two other patients. After desiccated thyroid administration, plasma T3 was unchanged in one patient but increased significantly (100%) in two others. Serum Ts in one patient, who was taking 60 mg desiccated thyroid per day, increased from a hypothyroid level (70 ng/100 ml) to an euthyroid value (142 ng/100 ml) after drug ingestion (Fig. 8 8-anilino-l-napththalene-sulfonic acid (18) . A physical method for the removal of the plasma binding proteins.
Sephadex column chromatography, was selected for the present studies since from published reports concerning the agents listed above, we were not certain that the added compounds completely blocked plasma protein binding in plasma with increased iodothyronine binding capacity. Moreover, one of the conmpounds, d,l-tetrachlorothyronine, may not be generally available in a pure and stable form.a At the time of this writing, however, there is insufficient experience with any of the reported assay procedures to allow generalizations regarding the superiority of any particular procedure with the exception that it appears important either to remove the plasma proteins or block their binding of Ta. a Evidence suggesting that the latter compound might contain or generate during standing sufficient d,l-trichlorothyronine, a T8 analogue, to displace Ts from antibody sites was obtained in two experiments performed in our laboratory before the present method was developed. In these, we noted displacement of tracer Ts from anti-Ts antibody by addition of d,l-tetrachlorothyronine (kindly supplied by Dr. Robert E. Meltzer, Warner-Lambert Research Laboratories, Compound W1633).
The assay procedure described herein satisfies a nunmber of criteria which are of cardinal importance for any Ts nmeasurement. First, Ts added to sera of widely different T3 concentrations was quantitatively recovered. Second, the calculated Ts concentrations of hypo-, eu-, and hyperthyroid sera were independent of the volume of serum applied to the columns. Third, conversion of T4 to Ts during the assay procedure was undetectable (<0.1%). Fourth, the capacity of the anti-Ta antibody to cross-react with endogenous T4 was also undetectable (< 0.1%). Fifth, as demonstrated from the identical standard curves run in different volumes of T3-free serum or 0.3% BSA, the Sephadex column procedure effectively removed all possible interfering substances from the plasma. Moreover, the Sephadex columns did not introduce any materials which alter the B/F ratio of tracer T3 and anti-T3 antibody. Finally, the precision of measurement within an assay, reproducibility between assays, and sensitivity of the assay system were all well within the limits required for both clinlical and investigative use.
The sensitivity of lP measurement by the Sephadex column procedure is substanitially imiiproved over published methods in which the volume of serunm which is assayed is generally limited to 0.1 ml (13, (15) (16) (17) . Without altering assay conditions, as much as 0.5 ml serunm can The dose was 120 mg/day in two subjects and 60 mg/day in a third (A-A). This subj ect (A-A) was the only patient in this series of experimenits who was socmewhat hypothyroid (serum TSH = 55 /U/ml).
be processed on the Sephadex columilinis. 'T'lie lowest limit of detection is approximately 6 ng '100 nil. lIndeed. tlhe T concentration in one patielnt in myvxedemna conma was 7 ng/100 ml] anid in a numhllzer of patients witlh severe hypothyroidismn was betweeln 10 and 25 ng/100 nml. The low T3 concentrations observed in severe hypothyroidism and lack of overlap between the hypotlhyroid and euthyroid range contrasts with other radioimmunioassays of T3 in which the reported mleani ±SD for hypotlhyroidl subjects was 103±43 (15) . 99±24 (17) . and 59±9 ng,' 100 ml (16 and in the absence of excess TSH stimulation, the normal gland secretes primarily T4. Under such circunmstances almost all T3 appears to he (lerived from the extrathyroidal conversion of T4. Tlhus, thle serum T3 conlcentrationi should be a more (lirect mzeasutre of thvroidal status than seruiii T4. Indeed, clinically euthvroid patients with decreased TL concentrationis but normal coI1-centrations of T, have beeni describe(d ly others (9) anl have been noted in ouir clinic too. The uise of serunm T in the assessmiieint of thvroidal status in hypothyroid patients receiving replacement therap)y with different thyroid hormiione preparations has not been enplihasizedI plreviously. The increase in seruni T3 concentration to the hyperthyroid racnge which was observe(d after ingestion of T; is sinmilar to that reported by Lieblich and Utiger (17) wvhile these stucdies were in progress. AAn increase in T:l concentratioin wvas also noted after ingestion of dlesiccated thyroid anI(d a T1: T, mixture but not after ingestion of T4. The (lifference in the magnitude of increase and time course of T3 concentration (luring therapy withl these mledications may be related to the cheiniical form of hormilone administered, the nature of tlle pharmaceutical preparation, the absorption of hormone by the patient, or a combination of these factors. Of particular interest, is that the mean plasma T, concentratioll calculated by integrating the area under the plasma T3 curves (Figs. 5-8 ) wvas significantly greater (200-290 ng/100 ml) thain the upper limit of the normal range for all patients who were clinically euthy'roid after treatment with T3. T4: T3 mixtures, or desiccated thyroidt. Although no direct data are currently available, possible deleterious effects on different organ systems of a modest increase in plasma T3 concentration sustained over the course of years should be considered. Until this problem is evaluated it would appear reasonable to use synthetic T4 for hormone replacement since the constancy of serum T3 and T4 after administration of this preparation most closely mimics the plasma hormone concentrations observed in euthvroid subjects throughout the day. It is clear, however, that if the other medications are employed, careful consideration must be given to the relationship of the time medications are ingested to that of blood sampling in order to obtain Ts concentrations which reflect the mean plasma hormone concentration and not a transient postabsorptive elevated value. Additional studies to assess the comparative adequacy of various thyroid hormone preparations in replacemenlt therapy are in progress.
